Abstract 419P
Background
Mammogram is a mandatory screening test for women from 40 years of age in the most parts of the world. While the structural screening for Coronary artery disease doesn’t exist but Women with breast cancer share common risk factors for coronary artery disease (CAD) as well. By using mammogram we can detect the potentially high risk patients, common for both the diseases and this is going to help in long way. Literature suggests that breast arterial classification exist in up to 8- 26% in women undergoing mammogram. In this study we have explored incidence of the total calcifications on mammogram and the percentage of people having Coronary artery diseases in a retrospective to manner.
Methods
It’s a retrospective observation of all mammograms done in past one year for routine screening from three institutes during the study period 2020-2021. Those with calcifications were interviewed and for the willing population we evaluated the coronary artery disease status clinically and radiologically. The mammogram calcifications were classified into mild, moderate, and severe as per the existing literature, so as the findings of the coronary angiogram. The incidence of the calcifications and the presence of CAD in the population were represented as percentages. Medcalc software version 10.1 was used for the analysis.
Results
There are 400 subjects whose complete case records besides the mammograms were available during the study period. Out of these patients 45 had some form of calcifications on mammograms with varying severity. Out of the 45 subjects 38 patients had coronary angiogram testing (either conventional or CT). We could observe 30 of them harboring moderate to severe atherosclerotic changes and varying degree of coronary artery stenosis.
Conclusions
Conclusion The results here hence strongly advocate the radiologists to report the same findings and should prompt the screening physician to encourage the patients for their cardiac risk assessment. In these multi-centre study patients with suspected coronary artery disease, our timely intervention changed the diagnosis and management of patients, who underwent mammogram for screening, but were unaware of the coronary disease, which led to improved outcomes on cardiac aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06